This article first appeared on GuruFocus.

Anika Therapeutics Inc (NASDAQ:ANIK) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $27.80 million, and the earnings are expected to come in at -$0.27 per share. The full-year 2025 revenue is expected to be $111.29 million, and the earnings are expected to be -$1.28 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 2 Warning Signs with ANIK.

Is ANIK fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for Anika Therapeutics Inc (NASDAQ:ANIK) for the full year 2025 have increased from $110.99 million to $111.29 million. However, for 2026, revenue estimates have declined from $116.92 million to $116.39 million. Earnings estimates have also seen a decline; for the full year 2025, they have decreased from -$1.18 per share to -$1.28 per share, and for 2026, they have dropped from -$0.67 per share to -$0.95 per share.

In the previous quarter ending June 30, 2025, Anika Therapeutics Inc's (NASDAQ:ANIK) actual revenue was $28.22 million, which beat analysts' revenue expectations of $27.03 million by 4.39%. Anika Therapeutics Inc's (NASDAQ:ANIK) actual earnings were -$0.28 per share, which missed analysts' earnings expectations of -$0.23 per share by -21.74%. After releasing the results, Anika Therapeutics Inc (NASDAQ:ANIK) was down by -27.42% in one day.

Based on the one-year price targets offered by 2 analysts, the average target price for Anika Therapeutics Inc (NASDAQ:ANIK) is $15.50, with a high estimate of $16.00 and a low estimate of $15.00. The average target implies an upside of 57.84% from the current price of $9.82.

Based on GuruFocus estimates, the estimated GF Value for Anika Therapeutics Inc (NASDAQ:ANIK) in one year is $22.32, suggesting an upside of 127.29% from the current price of $9.82.

Based on the consensus recommendation from 2 brokerage firms, Anika Therapeutics Inc's (NASDAQ:ANIK) average brokerage recommendation is currently 1.5, indicating a \\"Buy\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.